

A PHASE III RANDOMIZED TRIAL OF METFORMIN VERSUS PLACEBO ON RECURRENCE AND SURVIVAL IN EARLY STAGE BREAST CANCER

Study Number: MA.32

This is a clinical trial (a type of research study). Clinical trials include only patients who choose to take part. Please take your time to make your decision. Discuss it with your friends and family.

You are being asked if you would like to take part in this study because you have had surgery to remove a breast cancer. The usual treatment for breast cancer is either biologic therapy given by mouth or in a vein, some combination of chemotherapy (drugs given by mouth or in a vein), hormone therapy (usually a pill), both chemotherapy and hormone therapy and biologic therapy or occasionally no drug treatment. Depending on the size of the cancer you had, its appearance under the microscope and whether the cancer has spread to the lymph nodes (tissue in the armpit), there is a chance that breast cancer may eventually return. You should discuss with your physician how likely it is that your cancer will recur (come back).

This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with your other therapy to keep your cancer from recurring. Health Canada has not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.

WHY IS THIS STUDY BEING DONE?

The purpose of this study is to find out whether it is better to receive the drug Metformin, with the usual treatment for breast cancer, or not. To do this, half of the subjects in this study will get Metformin, in addition to their usual treatment. The other half will receive a placebo (a substance that will look identical to the Metformin pills but will not contain any active ingredients) in addition to their usual treatment.

This research is being done because previous laboratory work has shown that Metformin may decrease the growth of different types of cancer cells, including breast cancer cells. Research has also shown that Metformin lowers the level of insulin, a hormone found in the blood that can negatively affect breast cancer.

No information is yet available on whether Metformin may help prevent breast cancer recurrence in patients like yourself who have had their breast cancer removed by surgery. We do not know whether the use of Metformin will improve the usual treatment for breast cancer.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

HOW MANY PEOPLE WILL TAKE PART IN THE STUDY?

About 3582 people from the United States, Canada and other countries will take part in this study.

The study should take 3 years to complete enrollment and the results should be known in about 6 years.

WHAT IS INVOLVED IN THE STUDY?

Please see the Study Plan attached to the end of this consent form.

Randomization (assignment to a group):

If you decide to participate you will be "randomized" into one of the study groups described below. Randomization means that you are put into a group by chance. It is like flipping a coin. A central statistical office will be called which will assign one of the treatments to you. Neither you nor your doctor can choose what group you will be in. You will have an equal chance of being placed in either group.

This study is a double-blind study, which means that neither you nor your doctor will know if you are taking Metformin or placebo. In an emergency, if the treatment needs to be identified it will be.

Treatment:

Day	What you do
28 days prior to enrollment	Attend clinic appointment for check-up. Get routine blood tests (and any other tests your doctor considers necessary). Complete Questionnaires.
Within 10 working days after enrollment	Begin study treatment by taking one caplet a day for 4 weeks. *
4 weeks after enrollment	At the end of this initial 4 week period, begin taking two caplets per day, one in the morning and one in the evening, with food. Keep taking two caplets per day, in this manner, until the end of study, unless you experience side effects that are intolerable for you or you are told to stop by your health care team. Expect a telephone call from the clinic asking how you are feeling, whether you have been taking your study drug every day and if you, at the 4 week mark, have increased the dose to two caplets per day.
6 months after enrollment	Continue taking study drug, two caplets per day, by mouth – one in the morning and one in the evening. Attend clinic appointment for check-up. Get routine blood tests (and any other tests your doctor considers necessary). Complete questionnaires.
* For this period and the entire duration of your study treatment, missed doses should not be made up. If vomiting occurs within 2 hours after a metformin/[placebo tablet is swallowed, the dose should be replaced only if all of the intact tablet can be easily seen. Otherwise it should not be replaced and the next dose should be taken according to schedule.	

Continued on next page ...

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

Day	What you do
12 months after enrollment	Continue taking study drug, two caplets per day, by mouth – one in the morning and one in the evening. Attend clinic appointment for check-up. Get routine blood tests and a mammogram if you have not had one within the past year (and any other tests your doctor considers necessary). Complete questionnaires.
24 months after enrollment	Continue taking study drug, two caplets per day, by mouth – one in the morning and one in the evening. Attend clinic appointment for check-up. Get routine blood tests and a mammogram if you have not had one within the past year (and any other tests your doctor considers necessary). Complete questionnaires.
36 months after enrollment	Continue taking study drug, two caplets per day, by mouth – one in the morning and one in the evening. Attend clinic appointment for check-up. Get routine blood tests and a mammogram if you have not had one within the past year (and any other tests your doctor considers necessary). Complete questionnaires.
48 months after enrollment	Continue taking study drug, two caplets per day, by mouth – one in the morning and one in the evening. Attend clinic appointment for check-up. Get routine blood tests and a mammogram if you have not had one within the past year (and any other tests your doctor considers necessary). Complete questionnaires.
60 months after enrollment	Attend clinic appointment for check-up. Get routine blood tests and a mammogram if you have not had one within the past year (and any other tests your doctor considers necessary). Complete questionnaires. Stop taking study drug.

After Study Drug Has Stopped

Annually after stopping study drug	Attend clinic appointment for check-up. Get a mammogram if you have not had one within the past year (and any other tests your doctor considers necessary).
------------------------------------	---

Group 1: Metformin (Experimental Group)

If you are randomized to Group 1 you will receive Metformin in addition to your usual treatment. For the first 4 weeks, you will take one caplet by mouth every day. After this, you will take one caplet by mouth two times a day – one caplet in the morning and one in the evening. The caplets should be taken with food. The drug may be stopped temporarily or permanently if you suffer side effects that are unacceptable. You are encouraged to maintain a healthy weight and moderate degree of exercise (You will be provided, by the clinic, with some information to help you). You are also encouraged to consult your doctor or study nurse if you decide to stop study drug permanently.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

Group 2: Placebo (Standard Group)

If you are randomized to Group 2 you will receive Placebo in addition to your usual treatment. For the first 4 weeks, you will take one caplet by mouth every day. After this you will take one caplet by mouth two times per day – one caplet in the morning and one caplet in the evening. The caplets should be taken with food. The “drug” may be stopped temporarily or permanently if you suffer side effects that are unacceptable. You are encouraged to maintain a healthy weight and moderate degree of exercise (You will be provided, by the clinic, with some information to help you). You are also encouraged to consult your doctor or study nurse if you decide to stop study drug permanently.

Procedures and Medical Tests:

The following tests may be done at the hospital or clinic (or other location) to make sure that you are eligible for this study. None of these tests are experimental.

- Physical Examination
- Blood Tests
- Mammogram
- Chest X-ray (or CT Scan)
- CT Scan or Ultrasound of liver
- Bone Scan

You will be contacted by the clinic, by telephone, about one month after your enrollment to the study, so that the clinic can confirm that you are doing well and have moved up to the full dose of two pills per day. You will be seen by your doctor every 6 months during the first year and then every 12 months thereafter for clinical evaluation and to have routine blood and chemistry tests. You will be asked to return your old bottle of pills every time you receive a new one so that the pills remaining may be counted as a record of how many pills you took. Your doctor will monitor how well your kidneys are working, every year, by means of a blood test. You will also have a fasting glucose and insulin blood test which are not routine and specific to this research study.

The needles used to take blood or inject substances for body scans might be uncomfortable. You might get a bruise, or rarely, an infection at the site of the needle puncture.

Many of these tests will also be repeated during the study. Some of these tests may be done more frequently than if you were not taking part in this research study.

Note to sites: The following section, regarding questionnaires, is applicable only to the first 888 eligible English/French-speaking patients participating in the Quality of Life, Physical Activity and Diet Questionnaire component of the MA.32 protocol. An announcement will be sent to all sites when this component of the protocol has achieved its target accrual.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

Questionnaires:

You will be asked to complete some questionnaires before starting the study. If you speak or read English or French and you are physically able to complete the questionnaires, you must do so to be enrolled in the study.

You will be asked to fill out these questionnaires every 6 months for the first year and then annually while you are receiving treatment to understand how your treatment and illness affect your quality of life. These questionnaires ask about how you are feeling and take about 25 minutes to complete. There are also questions about physical activity and diet which will take an additional 15 minutes to complete. Some of the questions are personal; you can refuse to answer these if you wish. The information you provide is for research purposes only and will remain strictly confidential. The individuals (e.g. doctors, nurses, etc.) directly involved in your care will not usually see your responses to these questions - if you wish them to know this information please bring it to their attention.

Blood Samples

The researchers doing this study are interested in doing research tests on blood samples to look for markers (insulin and glucose levels) that might help predict which patients are most likely to be helped by the study drug Metformin. The collection of blood samples for this purpose is a mandatory part of this study.

Blood samples, taken with a needle from a vein in your arm, will be taken at the same time, as part of your main study related tests (at entry to the trial, at 6 months after enrollment and at the end of study treatment). An extra tablespoon of blood will be taken for glucose and insulin in addition to the 1 tablespoon for other routine blood tests. The needles used to take blood might be uncomfortable. You might get a bruise, or rarely, an infection at the site of the needle puncture.

One of these blood tests (called a fasting glucose test) will require that you do not eat or drink for 12 hours before the blood is taken.

The research blood samples will be collected by your research team. The fasting glucose level will be measured right away in your hospital's laboratory. The sample for insulin level will be collected by the NCIC Clinical Trials Group and then sent to a research laboratory and analyzed. The identification that will be on your blood samples sent to the NCIC CTG may include the study code, patient identification number and your initials. Blood sent to the laboratory and used for research is identified only by a special code to protect your identity and privacy. Samples will be used for this purpose only and will not be sold.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

HOW LONG WILL YOU BE IN THE STUDY?

Your treatment will last for about 5 years. The researchers can take you off the study treatment early for reasons such as:

- The treatment does not work for you and your cancer comes back or you develop a new cancer
- You are unable to tolerate the study treatment.
- New information shows that the study treatment is no longer in your best interest.
- Your doctor no longer feels this is the best treatment for you.
- Sponsor decides to stop trial

You may discontinue study medication at any time; however, you are encouraged to discuss this decision with your doctor or study nurse. No matter which group you are randomized to, and even if you stop treatment early, we would like to keep track of your health for the rest of your life to look at the long-term effects of the study treatments.

WHAT ARE THE RISKS OF THE STUDY?

While on the study, you are at risk for the side effects listed below. You should discuss these with your doctor. As with any experimental drug additional unexpected and sometimes serious side effects are a possibility.

Your doctor will watch you closely to see if you have side effects. When possible other drugs will be given to you to make side effects less serious and uncomfortable. Many side effects go away shortly after treatment is stopped but in some cases side effects can be serious, long-lasting or permanent.

Metformin is commonly used for diabetes treatment. It has been available in Canada for over 25 years. It is widely used in individuals with Type 2 diabetes, including patients with breast cancer who have diabetes. In general, metformin is safe and well tolerated. You should tell your doctor about other medications you are on, however, when you are considering participation in this study, so that your doctor can confirm if taking Metformin, with the medication you are already taking, is safe. You should not be taking sulfonylurea-type drugs (commonly used to treat diabetes) such as Acetohexamide, Chlorpropamide, Tobutamide, Tolazamide, Glipizide, Gliclazide, Glyburide, Gliquidone, Glycopyramide, Glimepiride, thiazolidinedione drugs (also used to treat diabetes) such as Avandia, Actos, or insulin for any reason. Side effects related to metformin include:

Most Likely: (greater than 20%):

- Diarrhea
- Nausea
- Vomiting
- Abdominal bloating
- Flatulence (gas)
- Anorexia (loss of appetite)

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

These symptoms are generally temporary, during the start of treatment, and disappear without stopping the drug.

Less likely [Occasional] (5 to 20%):

- Loss of taste or metallic taste (during start of therapy)
- Minor weight loss (less than 1 kilogram or 2 pounds)
- Reduced appetite

Rarely (1 to 4%):

- Rash, redness or itchiness
- Decrease in the level of a vitamin in your blood (called B12) that does not cause symptoms
- Decrease in your red blood cell count
- Liver function test abnormalities as seen by blood tests or hepatitis (inflammation of your liver) These effects will disappear when Metformin is stopped.

Rare but Serious (less than 1%):

- Lactic acidosis (a high acid level in the blood) occurs rarely (3 cases per 100,000 years of use) and can cause death. Individuals at risk of this complication include persons with diabetes who have kidney abnormalities, heart muscle abnormality or who are over 80 years of age. Symptoms of lactic acidosis may include tiredness, muscle aches, difficulty breathing, vomiting or severe abdominal pain. If you develop these symptoms or any serious medical condition while taking metformin, you should stop the medication and seek medical treatment - your regular physician or your local Emergency Department – the physician you see should be informed that you are taking metformin.

Risks you can help to reduce:

Reproductive: Because of the effects the metformin may have on a fetus are unknown, you should not become pregnant while on this study or father a child. An effective method of birth control should be used while you are on study treatment. This could include IUD, condoms or other barrier methods of birth control. Women who are postmenopausal, or have had a tubal ligation or men who have had a vasectomy do not need to use additional birth control. Ask about counseling and more information about preventing pregnancy. Women should not nurse a baby while on this study because it is possible the metformin may be present in breast milk.

Alcohol Consumption: In order to maximize the safety of this drug, you should not drink excessive alcohol while you are on it (we recommend that you limit your intake to less than 3 alcoholic beverages on any given day).

Medical Investigations and Hospitalizations: If you are scheduled for any x-ray tests (including CT Scans but not including MRI scans) that require intravenous contrast material, you should notify your breast cancer physician/surgeon and the study nurse – study drug should not be taken 24 hours before or two days after those procedures. Similarly, if you have any surgery, you should notify your breast cancer physician/surgeon and the study nurse – study drug should not be taken on the day of surgery or for the first 2 days after surgery. The study medication should be stopped while you are hospitalized for any reason.

A Data Safety Monitoring Board, an independent group of experts, will be reviewing the data from this research throughout the study.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

AMEND #1: 2011-AUG-15

ARE THERE BENEFITS TO TAKING PART IN THE STUDY?

If you agree to take part in this study, there may or may not be direct benefit to you. We hope the information learned from this study will help other patients with breast cancer in the future.

WHAT OTHER OPTIONS ARE THERE?

If you decide not to take part in this study, your doctor will discuss other treatment options with you. These may include receiving the usual treatment (chemotherapy, hormone therapy, biologic therapy or some combination of these or occasionally no drug treatment) without metformin or participation in another clinical trial.

Please talk to your doctor about the known benefits and risks of these other treatment options. Your doctor can also discuss with you what will happen if you decide not to undertake any treatment at this time.

WHAT ABOUT CONFIDENTIALITY?

Qualified representatives of the following organizations may inspect your medical/study records for quality assurance and data analysis:

- NCIC Clinical Trials Group (NCIC CTG), the research group coordinating this study
- The research ethics committee who oversees the ethical conduct of this study in your hospital/clinic
- U.S. Food and Drug Administration (because they oversee the use of drugs in the U.S.)
- National Cancer Institute of the U.S., the organization that oversees U.S. participation in this study
- Health Canada (because they oversee the use of drugs in Canada)
- U.S. Cooperative Groups participating in the trial (because they oversee trial conduct at their own institutions)

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

AMEND #1: 2011-AUG-15

Qualified representatives of the following organizations may receive information from your medical/study records for quality assurance and data analysis:

- NCIC Clinical Trials Group (NCIC CTG), the research group coordinating this study
- The research ethics committee who oversees the ethical conduct of this study in your hospital/clinic
- Apotex, the company that is providing the metformin and placebo for this clinical trial
- National Cancer Institute of the U.S., the organization that oversees U.S. participation in this study
- U.S. Food and Drug Administration (because they oversee the use of drugs in the U.S.)
- Health Canada (because they oversee the use of drugs in Canada)
- Other regulatory authorities (because they oversee the use of drugs in other countries)
- Central laboratory conducting correlative science
- U.S. Cooperative Groups participating in the trial (because they oversee trial conduct at their own institutions)
- Cancer Trials Support Unit (CTSU) , a research group sponsored by the National Cancer Institute (NCI) to provide greater access to clinical trials

This may contain information that could potentially identify you, and includes:

- test results
- reports of operations
- x-rays or other body scan reports
- reports about your treatment and side effects
- questionnaires (*Note to sites: include this bullet only for as long as the 888 subjects participating in the Quality of Life, Physical Activity and Diet Component of this clinical trial are being enrolled.*)

CT/MRI scans and x-rays may also be reviewed to confirm response to treatment.

The organizations listed above will keep the information they see or receive about you confidential, to the extent permitted by applicable laws. Identifying information will be kept behind locked doors. Identifying information will never be included in a publication of the research.

The information collected during this study will be used in analyses and will be published/ presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of metformin as used in this research. It is expected that the study results will be published in 2016. Your study doctor will be informed of the results of the study once they are known.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

WHAT ARE THE COSTS?

The study drug, Metformin (or placebo), will be given to you free of charge as long as you receive treatment on the study.

You will not be paid for taking part in this study. Taking part in this study may result in added costs to you.

In the case of research-related side effects or injury, medical care will be provided by your doctor or you will be referred for appropriate medical care. Although no funds have been set aside to compensate you in the event of injury or illness related to the study treatment or procedures, you do not waive any of your legal rights for compensation by signing this form.

WHAT ARE YOUR RIGHTS AS A PARTICIPANT?

Taking part in this study is voluntary. You may choose not to take part or may leave the study at any time. Deciding not to take part or deciding to leave the study later will not result in any penalty or any loss of benefits to which you are entitled. If you decide to stop participating in the study, we encourage you to talk to your doctor first. Your doctor will discuss further treatments with you and continue to treat your cancer with the best means available.

You will be told, in a timely manner, about new information that may affect your health, welfare, or willingness to stay in this study.

You will be given a copy of this signed and dated consent form.

CONFLICT OF INTEREST

Note to centres: Please include details of any actual or potential conflict of interest concerning this study.

This centre is receiving funds from the NCIC Clinical Trials Group to help offset the costs of conducting this research. NCIC CTG is a non-profit research group.

WHO DO YOU CALL IF YOU HAVE QUESTIONS OR PROBLEMS?

If you have questions about taking part in this study or if you suffer a research-related injury you can talk to your doctor. Or, you can meet with the doctor who is in charge of the study at this institution. That person is:

Name

Telephone

If you would like advice regarding your rights as a patient or about ethical issues related to this study, you can talk to someone who is not involved in the study at all. That person is:

Kansas City Clinical Oncology Program at 913-948-5588

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

AMEND #1: 2011-AUG-15

SIGNATURES

My signature on this consent form means the following:

- The study has been fully explained to me and all of my questions have been answered,
- I understand the requirements and the risks of the study,
- I authorize access to my medical records as explained in this consent form, and
- I agree to take part in this study.

Signature of Patient

Date

Signature of Person Conducting
Consent Discussion

Name of Person Conducting
Consent Discussion

Date

Was the patient assisted during the consent process in one of the ways listed below?

Yes No

If yes, please check the relevant box and complete the signature space below:

The consent form was read to the patient, and the person signing below attests that the study was accurately explained to, and apparently understood by, the patient.

The person signing below acted as a translator for the patient, during the consent process.

Signature of Person Assisting in
the Consent Discussion


Date

Please note: More information regarding the assistance provided during the consent process should be noted in the medical record for the patient if applicable.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

Study Plan

Another way to find out what will happen to you during the study is to read the study plan below. Start reading at the top and read down the list, following the arrows.



Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

ENGLISH Sample Consent Form – Tissue and Blood Collection and Banking

A PHASE III RANDOMIZED TRIAL OF METFORMIN VERSUS PLACEBO ON
RECURRENCE AND SURVIVAL IN EARLY STAGE BREAST CANCER

Study Number: MA.32

Le formulaire de consentement est disponible en français sur demande.

Note to centre: If an REB approved French consent is not used at your institution you should remove the above statement.

Tissue and Blood Collection and Banking

Optional Tissue Banking:

The researchers doing this study are interested in doing research studies on tissue samples from your diagnostic cancer specimen. For example, research that may help us better understand the nature of cancer and how patients respond to treatment. The research that may be done with your tissue may not directly benefit you. It may help people in the future who have the same kind of cancer as you have. You may refuse to have your tissue banked and still participate in the main study.

The collection of breast cancer tissue that has already been removed by biopsy or surgery is an optional part of the study. No further surgeries or biopsies are required of you for this purpose.

Examples of planned research for tumour tissue include: 1) the measurement of insulin receptors – molecules on the surface of cells that bind insulin and help transport insulin into the cell; 2) the measurement of an enzyme called LKB1, an indicator of cell growth in tumour cells; 3) the measurement of certain proteins in the cell, called phosphoantibody markers, that reveal whether or not certain molecular pathways are active; 4) an examination of the genes expressed in tumour cells to determine if any of them are predictive of a response to metformin.

Any tissue samples collected will be stored at a central tissue bank (a facility where tissues, including tumours and blood, are stored for future research) located at Queen's University in Kingston, Ontario. The samples will be kept indefinitely or until they are returned to the hospital where you had your surgery or biopsy. The identification that will be on your tissue samples sent to the NCIC Clinical Trials Group may include your study code, patient identification number, initials and pathology identification number. Samples sent to researchers will be identified only by a unique number assigned by the NCIC CTG Tissue Bank. This number is referred to as a tumour bank code and is used to ensure your personal identifiers will not be available to researchers.

BLOOD COLLECTION

Blood collection is mandatory for participation in this clinical trial so that insulin and glucose levels can be measured. This was described in the main consent form.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

The researchers doing this study are also interested in doing research on additional, optional blood samples to be taken before you start treatment, six months after you start treatment and at the end of treatment. This research may help us understand who will benefit the most from Metformin treatment. Researchers may also wish to do other research on your blood samples. The research that may be done with your blood may not directly benefit you. It may help people in the future who have the same type of cancer as you have. You may refuse to have your samples banked for future research and still may participate in the main study.

This means an additional 2-3 tablespoons (35 ml) of blood taken with a needle from a vein in your arm will be collected in addition to the study-related blood samples. The needles used to take blood might be uncomfortable. You might get a bruise or rarely, and infection at the site of the needle puncture.

Any blood samples collected will be stored at a central tissue bank (a facility where tissues, including tumours and blood, are stored for future research) located at Queen's University in Kingston, Ontario. The samples will be kept until they are used up. The identification that will be on your blood samples sent to the NCIC Clinical Trials Group may include your study code, patient identification number and initials. Samples sent to researchers will be identified only by a unique number assigned by the NCIC CTG Tissue Bank. The number is referred to as a bank code and is used to ensure your personal identifiers will not be available to researchers.

WHAT ARE YOUR RIGHTS AS A PARTICIPANT?

You may choose not to take part or may at any time withdraw your consent for this portion of the study and ask that the collected samples not be used. Deciding not to take part or deciding to withdraw your consent for this portion of the study later will not result in any penalty or loss of benefits to which you are entitled. If you decide to stop participating and no longer want your samples to be used in this research, you should tell your doctor. Your doctor will notify the NCIC Clinical Trials Group (NCIC CTG) who will ensure the blood samples are destroyed and tissue samples are returned to the hospital where you had your original biopsy or surgery. If tests have already been done with your sample and included in an analysis or publication, it will not be possible to withdraw these.

All the information provided in the main study consent form about confidentiality, costs, your rights as a participant, and who to contact with questions, applies to this tissue and blood collection and banking consent form as well.

The research done with your samples may or may not help develop commercial products or tests. There are no plans to provide payment to you if this happens.

Reports about any research done with your samples will not be given to you or your doctor. These reports will not be put in your medical records. The research using your samples will not affect your care.

In the future, people who do research with your sample may need to know more about your health. While the researchers coordinating this study may give them reports about your health, they will not give them your name, address, phone number or any other information that will let them know who you are.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

WILL GENETIC TESTING BE DONE ON MY TISSUE SAMPLES?

All cancers are caused by changes in our genes or by changes in when or how these genes are expressed. NCIC CTG does not consider the study of changes in the genetic material of cancer cells to be "genetic research", as these changes are acquired after you are born and not passed on in families. This type of testing may be done on your samples if you agree to allow your samples to be banked for future research.

Some changes in genes that are inherited may determine the way a person will respond to treatment. These changes may also determine what kind of side effects a person will have when they receive different kinds of treatment. These genetic changes do not cause cancer or other diseases and the study of these changes is not considered by the NCIC CTG to be "genetic testing". This type of testing may be done on your samples if you agree to allow your samples to be banked for future research.

Some cancers are a result of genetic changes that are inherited (passed on in families). Some genes that are inherited may determine a person's chance of developing a particular disease, including cancer. Studies to look for these inherited genes that may cause cancer or other diseases are considered "genetic testing". As part of future studies, researchers may want to study the genetic material that is inherited through families and that may cause cancer or other diseases. This type of testing may be done on your samples if you agree to allow your samples to be used for future "genetic testing".

Participating in "genetic testing" (testing for inherited genes that may cause cancer or other diseases) can involve risks for participants and their families. If you are identified as belonging to a high-risk group for developing a specific disease it could affect employment, health or life insurance, or might alter decisions about having children. This is why "genetic testing" results are not given to you, they are not put into your medical records and every effort will be made to protect the privacy and confidentiality of these results. The chance of genetic test results being released in a way that can be linked to you is very small, however you should be aware of the risks. If you do not wish to have your samples used for "genetic testing" you may indicate your wish at the end of this consent form.

Approval Date: 12/15/11 to 7/13/12
Assurance #: FWA00003582

AMEND #1: 2011-AUG-15

SIGNATURES

<input type="checkbox"/> I agree to allow tissue samples from my tumour to be collected for the purposes described here. <input type="checkbox"/> I do not agree to allow tissue samples from my tumour to be collected for the purposes described here.

<input type="checkbox"/> I agree to allow blood samples to be collected for the purposes described here. <input type="checkbox"/> I do not agree to allow blood samples to be collected for the purposes described here.

<input type="checkbox"/> I agree to allow my samples to be used for genetic testing to see if my cancer may be hereditary. <input type="checkbox"/> I do not agree to allow my samples to be used for genetic testing to see if my cancer may be hereditary.

PLEASE CHECK THE APPROPRIATE BOX ABOVE BEFORE SIGNING

_____	_____
Signature of Patient	Date

_____	_____	_____
Signature of Person Conducting Consent Discussion	Name of Person Conducting Consent Discussion	Date

Was the patient assisted during the consent process in one of the ways listed below?

Yes No

If yes, please check the relevant box and complete the signature space below:

- The consent form was read to the patient, and the person signing below attests that the study was accurately explained to, and apparently understood by, the patient.
- The person signing below acted as a translator for the patient, during the consent process.

_____	_____
Signature of Person Assisting in the Consent Discussion	Date

Please note: More information regarding the assistance provided during the consent process should be noted in the medical record for the patient if applicable.

Approval Date: <u>12/5/11</u> to <u>7/13/12</u> Assurance #: FWA00003582
